Core Insights - The company experienced a 29% unit growth in Oncology diagnostics, with management noting acceleration throughout the fiscal year [1] - The Data business exceeded expectations with a 69% growth in the quarter, driven by a proprietary dataset of over 450 petabytes of connected multimodal data [1] - Management highlights a competitive advantage through a 'flywheel' effect, utilizing diagnostic data to train AI models and delivering insights back to physicians via 5,500 hospital connections [1] - The Insights (licensing) business achieved a net revenue retention of 126%, indicating significant year-over-year spending increases from existing pharma clients [1] - The strategic positioning aims to be a 'comprehensive solution' akin to an e-commerce giant, providing services from risk management to therapy selection and monitoring [1] - Operational efficiency is improving as the company shifts volume from Laboratory Developed Tests (LDTs) to FDA-approved versions of their xT CDx assay [1]